A newly formed network of 18 clinical centers in the United States,
Canada, Europe, and Australia is launching clinical studies on type 1 diabetes.
The network, Type I Diabetes TrialNet, has initiated two trials, one to understand
the biological basis of type 1 diabetes and the other to preserve insulin-secreting β
cells in patients newly diagnosed with the disease.
Researchers have been studying the genetic and immune markers for type
1 diabetes for years, and now they hope these efforts will be used to help
prevent the disease or stop it from progressing after diagnosis.
Hampton T. Type 1 Diabetes Trials. JAMA. 2004;292(4):426. doi:10.1001/jama.292.4.426-d